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Phenotypic characterisation by immunohistochemistry 
Figure 2. Isolated cells stained positive (green) for endothelial markers
and negative for muscular markers. Nuclei were stained by DAPI (blue).
AF488 Goat Anti-mouse fluorophore-conjugated antibody was used.
HPAE (human pulmonary arterial endothelial cells); SMC (smooth muscle
cells).
Phenotypic characterisation by flow cytometry  
Figure 3. Representative histograms show expression of surface markers 
associated with endothelial cells  and muscular cells on HPAE, SMC and 
CTEPH. EC-CTEPH were positive for all endothelial markers and negative 
for muscular markers. 
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Figure 4. EC-CTEPH showed a hyperproliferative phenotype (A-B) with
significantly higher and durable viability assayed by MTT assay (C). HPAE
were used as controls. N=10, data are expressed as mean ± SD. * p<0.05
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Figure 5. Images of wound-healing of HPAE and EC-CTEPH after 24
hours. Representative graph showing quantification of the % of covered area
over time for both EC-CTEPH and HPAE. N=10, * p<0.05 .
Metabolism  
Figure 6. Diagram
showing the glycolysis
pathway. EC-CTEPH have
higher amount of lactate in
the supernatant (SN) and a
higher LDH activity as
well when compared with
HPAE. * p<0.05. (LDH:
lactate dehydrogenase)
Endothelial markers Muscular markers 
Conclusion
1. Isolated CTEPH cells are confirmed as being endothelial cells.
2. EC-CTEPH show a hyperproliferative phenotype.
3. Functionally, EC-CTEPH have a reduced capacity to migrate.
4. Alterations in metabolism are being investigated after selection of key players.
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a pulmonary vascular
disease caused by chronic obstruction of pulmonary arteries. Pulmonary endarterectomy
(PEA) is the golden standard therapy for CTEPH patients. During PEA surgery
obstructive thromboembolic material from the pulmonary arteries is removed, including
intima and superficial media. This material offers a unique opportunity to study CTEPH
at disease side. Endothelial cells line the entire vascular system and are essential for
maintaining the vascular homeostasis. Remodeling of pulmonary arteries through
proliferation of endothelial cells plays a major role in the pathogenesis of pulmonary
hypertension.
Aim
We aim to develop an in vitro model of CTEPH using
patient derived endothelial cell (EC-CTEPH) lines
after PEA and assay changes in metabolism to
elucidate a hyperproliferative phenotype that could
explain vascular changes occurring in CTEPH.
Methods
Freshly obstructive thromboembolic material obtained after PEA from CTEPH
patients is used for cell isolation. These PEA samples are minced into 1-2 mm
pieces and cultured in 0.2% gelatine coated 6-well plates in EGM-2 endothelial
medium (Lonza) at 37°C, 5% CO2 and 95% relative humidity. Colonies
appeared within 1-3 weeks of culture.
• Phenotypic characterisation: immunohistochemistry and flow
cytometry quantified expression of endothelial markers.
• Cell growth kinetics: cells were plated at a concentration of 3x104 in
24-well gelatine coated plates in 1mL of EGM-2 media. At each
subsequent passage, cells were counted and plated again at the same
cell concentration. Cell migration was measured by wound-healing
assay and expressed as the % of covered area.
• Metabolic changes were examined using RT-PCR.
Figure 1. Material obtained after PEA from CTEPH patients
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